VivoSeq
Other

NK Cell

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

NK Cell is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

9/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed5 · 45%
Unknown status4 · 36%
Recruiting1 · 9%
Withdrawn1 · 9%

Clinical Trials

Trial Activity

11 trials

CIML NK Cells With Venetoclax for AML
Recruiting·—·Phase 1·NCT06152809·10 enrolled
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT03019666·39 enrolled
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT03383055·28 enrolled
Adoptive Transfer of Haploidentical NK Cells and N-803
Completed·UUniversity of Minnesota·Phase 1·NCT03899480·9 enrolled
The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs
Completed·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 1·NCT03188276·52 enrolled
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs
Completed·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03063723·25 enrolled
N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV
Withdrawn·UUniversity of Minnesota·Phase 1/2·NCT04144335
IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
Unknown status·—·N/A·NCT04482777·90 enrolled
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
Unknown status·—·Phase 2·NCT02452697·36 enrolled
Effects of Anesthetic Technique on NK Cells
Unknown status·—·N/A·NCT02669186·20 enrolled
Allogenic NK Cell Transfusion Azacitidine MDS-EB
Unknown status·TThe Second Hospital of Shandong University·Phase 1/2·NCT04599426·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)